Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating income | -$1.99M | -$12.0M | -$11.6M | -$17.0M |
| Net income | -$1.99M | -$15.4M | -$11.4M | -$16.7M |
| Fiscal year | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|
| Operating cash flow | -$1.85M | -$6.60M | -$8.26M | -$12.3M |
| Capital expenditures | $0.00 | $19.0K | $14.0K | $10.0K |
| Free cash flow | -$1.85M | -$6.62M | -$8.27M | -$12.3M |
| Fiscal year | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|
| Cash & equivalents | $865K | $8.61M | $9.14M | $7.00M |
| Total assets | $865K | $9.41M | $9.81M | $7.60M |
| Total liabilities | $221K | $1.78M | $1.71M | $1.71M |
| Shareholders' equity | $644K | $7.63M | $8.10M | $5.89M |
| Retained earnings | -$23.5M | -$39.0M | -$50.4M | -$67.1M |
| Shares (wtd avg diluted) | 12.0M | 1.04M | 1.77M | 7.22M |
Every figure is extracted from Autonomix Medical, Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.